The first stop for professional medicines advice

Medicines planning

40 results

Applied filters

National Homecare Medicines Committee (NHMC) Proposal for the funding of Pharmacy Homecare Teams

4 May 2018NHMC submitted a proposal for the funding of Trust Pharmacy Homecare Teams to NHS England and NHS Clinical Commissioning for consideration. The NHMC hopes that…

National Homecare Medicines Committee (NHMC) Homecare Risk Assessment

10 December 2019To support organisations in establishing a robust risk assessment process for new homecare medicines services the NHMC has developed a tool for local use.  …

NHMC Good Practice Principles for the Provision of Manufacturer Funded Homecare Services

5 March 2018These Good Practice Principles set out the National Homecare Medicines Committee’s (NHMC) expectations of Manufacturers offering Manufacturer Funded Homecare Medicine Services in relation to the…

Preparing to use natalizumab biosimilar

6 February 2024Natalizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team.

Preparing to use eculizumab biosimilar

6 March 2024Introducing biosimilar eculizumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.

Good governance when implementing ranibizumab biosimilar

29 June 2022Governance should consider processes for approval; procurement and supply; prescribing and administration; monitoring; and pharmacovigilance

The licence and supporting evidence for ranibizumab biosimilars

29 June 2022Four licensed ranibizumab biosimilars are available: Byooviz, Ongavia, Rimmyrah and Ximluci. Learn about the licensed indications and supporting evidence

Good governance when implementing ustekinumab biosimilar

2 August 2024Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.

Preparing to use ustekinumab biosimilar

16 July 2024Introducing biosimilar ustekinumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.

The licence and supporting evidence for ustekinumab biosimilars

2 August 2024Ustekinumab biosimilars (Pyzchiva, Steqeyma, Uzpruvo, Wezenla) are licensed. Learn about indications, formulations, supporting evidence and differences.